Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04331886 · ClinicalTrials.gov registry record

An Observational Study of Patients With Coronavirus Disease 2019

A clinical trial, sponsored by Target PharmaSolutions.

Completed
Registry status
199
Enrollment target

NCT04331886: Completed study, sponsored by Target PharmaSolutions.

NCT04331886 is a clinical trial that has completed, run by Target PharmaSolutions. The registered enrollment target is 199 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04331886 has completed, sponsored by Target PharmaSolutions.

COMPLETED
Registry status
199 participants
Enrollment target

Study Summary

This is an observational study of patients with COVID-19 designed to specifically address important clinical questions that remain incompletely answered for coronavirus disease 2019.

Trial Details

FieldValue
Enrollment Target 199 participants
Start Date 2020-04-13
Est. Completion 2022-09-26
Target PharmaSolutions

10 total trials

What the finished NCT04331886 record still lists

NCT04331886 is an observational study that tracks outcomes without assigning an intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT04331886 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04331886 about?

NCT04331886 is a clinical study titled "An Observational Study of Patients With Coronavirus Disease 2019". This is an observational study of patients with COVID-19 designed to specifically address important clinical questions that remain incompletely answered for coronavirus disease 2019.

What is the current status of trial NCT04331886?

This trial is currently completed. The enrollment target is 199 participants. The study started on 2020-04-13. Estimated completion is 2022-09-26.

Who is sponsoring clinical trial NCT04331886?

This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04312126 · 199 participants

    The Beneficial Effects of Naps on Motor Learning

  • NCT04951622 · 199 participants · Phase 3

    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  • NCT06474533 · 199 participants

    Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04331886, the US trial registry maintained by the National Library of Medicine. NCT04331886 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.